drugset / Trial / NCT00975299

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers

NCT00975299 ↗

Phase 1 Terminated 16 enrolled Bayer
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-4367 in patients with cancer

Timeline

Start
2009-09
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BAY86-4367 Diagnostic / imaging agent 300 mbq Intravenous

Indications

No indication recorded.